N1,N12-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers
N1,N12-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers
复制标题
N1,N12-二乙酰精胺作为早期和晚期结直肠癌和乳腺癌的一种敏感而特异的新型标记物
DOI：
10.1158/1078-0432.ccr-04-2275
复制
发表时间：
2005-04-15
影响因子：
11.5
通讯作者：
Kawakita, M
中科院分区：
文献类型：
--
作者：
Hiramatsu, K;Takahashi, K;Kawakita, M
目的：检测结直肠癌和乳腺癌患者尿液中的n - 1，n -12-二乙酰精胺（DiAcSpm），以确定其作为临床早期检测这些癌症的新诊断工具的有效性。实验设计：收集1999年8月~ 2004年1月在东京都Komagome医院接受治疗的248例结肠癌患者、83例乳腺癌患者和51例良性胃肠道疾病患者的尿液样本。ELISA法分析DiAcSpm，并与血清癌胚抗原（CEA）、CA19-9、CA15-3对恶性肿瘤的敏感性进行比较。结果：248例结肠癌患者尿DiAcSpm的敏感性为75.8%（以52例健康对照为截断值，平均+/- 2 SD），明显高于血清CEA （39.5%, P < 0.0001）和CA19-9 （14.1%, P < 0.0001）。DiAcSpm在60%的肿瘤淋巴结转移癌0 + 1期患者中升高，而CEA-和ca19 -9阳性患者分别只有10% （P < 0.0001）和5% （P < 0.0001）。83例乳腺癌患者尿DiAcSpm的敏感性（60.2%）高于CEA （37.3%, P = 0.0032）和CA15-3 （37.3%, P = 0.0032）。DiAcSpm在I + II期肿瘤转移患者中升高的比例为28%，而CEA-和CA15-3阳性的比例分别为3% （P = 0.0064）和0% （P = 0.001）。结论：尿DiAcSpm是一种比CEA、CA19-9和CA15-3更敏感的标志物，可以有效地检测早期结直肠癌和乳腺癌。
Purpose: N-1,N-12-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.Experimental Design: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected. DiAcSpm was analyzed by ELISA and its sensitivity for malignant conditions was compared with that of serum carcinoembryonic antigen (CEA), CA19-9, and CA15-3.Results: The sensitivity of urinary DiAcSpm for colon cancer patients (n = 248) was 75.8% (mean +/- 2 SD for 52 healthy controls as a cutoff value), which was markedly higher than the sensitivities of serum CEA (39.5%, P < 0.0001) and CA19-9 (14.1%, P < 0.0001). DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + 1 patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively. The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032). DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively,Conclusion:The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.